BioSpace News Archive

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx,”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 22nd MEDEXPO Africa 2022, held June 9-11 in Nairobi, Kenya.

The global antiviral drugs market size is expected to reach USD 50.02 Billion in 2030 and register a revenue CAGR of 3.4% during the forecast period, according to latest report by Reports and Data.

Critical Path Institute announced it has been awarded a grant from the Frederick Gardner Cottrell Foundation, a non-profit organization established by Research Corporation Technologies, Inc. that provides financial support for scientific research and educational programs, to create the C-Path Translational Therapeutics Accelerator.

The Global Cancer Stem Cells Market size is estimated to reach USD 2.98 Billion from USD 1.14 Billion in 2021, delivering a growth rate of 11% through 2030, according to a new report by Reports and Data.

The global colchicine market size is expected to reach USD 2,552.84 Million in 2030 and register a revenue CAGR of 8.4%, according to the latest report by Reports and Data.

The global live cell imaging market is expected to reach USD 4.26 billion in 2030 and register a revenue CAGR of 8.7% during the forecast period, according to latest report published by Reports and Data.

Tiziana Life Sciences PLC announced positive clinical results for its second secondary progressive multiple sclerosis patient in a June 8th press release.

Lipogems is pleased to announce the unconditional approval by the U.S. Food and Drug Administration (FDA) to conduct an Investigational Device Exemption (IDE) study for treatment of knee osteoarthritis (OA) compared to corticosteroids for a period of 12 months.

In accordance with the press release published on 9 June 2022, Mentice AB, has entered into an agreement to acquire all assets relating to the software solution Ankyras from Galgo Medical S.L., which was conditional on the receipt of external financing.

Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Aurobindo to resolve the dispute over Aurobindo’s Abbreviated New Drug Application (“ANDA”) for a generic deutetrabenazine product.